Domestic Dominance in Long-Acting Growth Hormone
China is a world leader in the development of Long-Acting Recombinant Human Growth Hormone (rhGH). While daily injections were the standard for decades, 2026 has seen the widespread adoption of "weekly" formulations produced by domestic pharmaceutical giants based in Changchun and Shanghai.
These formulations utilize PEGylation or fusion protein technology to extend the hormone's half-life in the body. This is a critical advancement for the Chinese market, as it improves treatment compliance among students in high-pressure school environments who often find daily injections difficult to maintain. The steady release of the hormone via weekly doses has been shown to achieve "catch-up growth" rates that are comparable to, or in some cases better than, traditional daily therapy.